Here are 10 stocks, covered by at least 10 brokerages, which are most likely to zoom based on their price target over the next year
Domestic firms may outperform exports in March quarter and in FY25
Yet, positioned for revenue growth with recent strong deals, driven by a strengthening US economy
Firm may face tough times amid forecast of weak box-office collections
In the past a rise in crude oil prices has resulted in lower corporate margins and profits
Even as the top pharmaceutical peers delivered a double digit growth in the December quarter, sales for GSK Pharma at Rs 805 crore was flat
Cheaper raw material prices and growth in premium segment expected to help company
Alchemy of revival: Early recovery catalysts blend with stable prices and eased supplier tensions
Brokerages are positive on the stock given its attractive valuations and expect a re-rating if there is value unlocking for its IPL franchise
The selloff in the small and midcap stocks has led to a moderation in valuation in the segment
Airline maps out its FY25 route, powered by double-digit pax growth, 11-13% year-on-year capacity boost, and expansion into 10 new destinations
Centrum Research believes that the company has sufficient operating levers that will help it report a higher margin in FY25 vs FY24
Analysts believe the company's growth trajectory remains intact, but current valuations imply that near-term growth prospects are priced in
The December quarter performance was impacted by the weak showing in the athleisure category
The demand-supply imbalance and margin pressures would be a key monitorable in the near to medium-term
Brokerages foresee smooth ride for passenger vehicle maker, with SUV dominance, EV entry on the horizon, and Suzuki Motor Gujarat consolidation
Brokerages administer confidence boost, elevating EPS forecasts and target prices for 2024-25
This was the fourth consecutive quarter of a decline in LFL growth for the pizza market leader
High stock valuation is another hurdle for the manufacturer of adhesives and construction chemicals
Punchy valuations threaten to limit stock gains